Review





Similar Products

bx 795  (InvivoGen)
95
InvivoGen bx 795
Bx 795, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bx 795/product/InvivoGen
Average 95 stars, based on 1 article reviews
bx 795 - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
cortical astrocytes  (BrainXell inc)
99
BrainXell inc cortical astrocytes
Cortical Astrocytes, supplied by BrainXell inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cortical astrocytes/product/BrainXell inc
Average 99 stars, based on 1 article reviews
cortical astrocytes - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier
bx 912  (MedChemExpress)
94
MedChemExpress bx 912
PRKDC and SLC25A13‐oriented drug framework identification for ESCC patients. (A) GSCA enrichment analysis for identification of sensitive drugs targeting PRKDC and SLC25A13. (B,C) Sensitivity analysis of drugs for ESCC patients. (D) CCK‐8 assays for optimum concentration of Navitoclax <t>and</t> <t>BX‐912</t> in KYSE150 cell lines. (E) CCK‐8 assay for evaluation of Navitoclax and BX‐912 in KYSE150 cell line growth. (F) Wound‐healing assays following Navitoclax and BX‐912 treatment in KYSE150 cells. Data was presented as mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bar = 200 μm.
Bx 912, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bx 912/product/MedChemExpress
Average 94 stars, based on 1 article reviews
bx 912 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
navitoclax  (MedChemExpress)
94
MedChemExpress navitoclax
PRKDC and SLC25A13‐oriented drug framework identification for ESCC patients. (A) GSCA enrichment analysis for identification of sensitive drugs targeting PRKDC and SLC25A13. (B,C) Sensitivity analysis of drugs for ESCC patients. (D) CCK‐8 assays for optimum concentration of <t>Navitoclax</t> and BX‐912 in KYSE150 cell lines. (E) CCK‐8 assay for evaluation of Navitoclax and BX‐912 in KYSE150 cell line growth. (F) Wound‐healing assays following Navitoclax and BX‐912 treatment in KYSE150 cells. Data was presented as mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bar = 200 μm.
Navitoclax, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/navitoclax/product/MedChemExpress
Average 94 stars, based on 1 article reviews
navitoclax - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
midbrain dopaminergic neurons  (BrainXell inc)
90
BrainXell inc midbrain dopaminergic neurons
PRKDC and SLC25A13‐oriented drug framework identification for ESCC patients. (A) GSCA enrichment analysis for identification of sensitive drugs targeting PRKDC and SLC25A13. (B,C) Sensitivity analysis of drugs for ESCC patients. (D) CCK‐8 assays for optimum concentration of <t>Navitoclax</t> and BX‐912 in KYSE150 cell lines. (E) CCK‐8 assay for evaluation of Navitoclax and BX‐912 in KYSE150 cell line growth. (F) Wound‐healing assays following Navitoclax and BX‐912 treatment in KYSE150 cells. Data was presented as mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bar = 200 μm.
Midbrain Dopaminergic Neurons, supplied by BrainXell inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/midbrain dopaminergic neurons/product/BrainXell inc
Average 90 stars, based on 1 article reviews
midbrain dopaminergic neurons - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
microglia  (BrainXell inc)
99
BrainXell inc microglia
PRKDC and SLC25A13‐oriented drug framework identification for ESCC patients. (A) GSCA enrichment analysis for identification of sensitive drugs targeting PRKDC and SLC25A13. (B,C) Sensitivity analysis of drugs for ESCC patients. (D) CCK‐8 assays for optimum concentration of <t>Navitoclax</t> and BX‐912 in KYSE150 cell lines. (E) CCK‐8 assay for evaluation of Navitoclax and BX‐912 in KYSE150 cell line growth. (F) Wound‐healing assays following Navitoclax and BX‐912 treatment in KYSE150 cells. Data was presented as mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bar = 200 μm.
Microglia, supplied by BrainXell inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/microglia/product/BrainXell inc
Average 99 stars, based on 1 article reviews
microglia - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier
olympus bx  (Evident Corporation)
99
Evident Corporation olympus bx
PRKDC and SLC25A13‐oriented drug framework identification for ESCC patients. (A) GSCA enrichment analysis for identification of sensitive drugs targeting PRKDC and SLC25A13. (B,C) Sensitivity analysis of drugs for ESCC patients. (D) CCK‐8 assays for optimum concentration of <t>Navitoclax</t> and BX‐912 in KYSE150 cell lines. (E) CCK‐8 assay for evaluation of Navitoclax and BX‐912 in KYSE150 cell line growth. (F) Wound‐healing assays following Navitoclax and BX‐912 treatment in KYSE150 cells. Data was presented as mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bar = 200 μm.
Olympus Bx, supplied by Evident Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/olympus bx/product/Evident Corporation
Average 99 stars, based on 1 article reviews
olympus bx - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier

Image Search Results


PRKDC and SLC25A13‐oriented drug framework identification for ESCC patients. (A) GSCA enrichment analysis for identification of sensitive drugs targeting PRKDC and SLC25A13. (B,C) Sensitivity analysis of drugs for ESCC patients. (D) CCK‐8 assays for optimum concentration of Navitoclax and BX‐912 in KYSE150 cell lines. (E) CCK‐8 assay for evaluation of Navitoclax and BX‐912 in KYSE150 cell line growth. (F) Wound‐healing assays following Navitoclax and BX‐912 treatment in KYSE150 cells. Data was presented as mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bar = 200 μm.

Journal: Cancer Medicine

Article Title: Identification and Validation of cGAS ‐ STING Pathway‐Associated Predictive and Therapeutic Models for Esophageal Squamous Cell Cancer Patients via Artificial Intelligence and Multi‐Omics

doi: 10.1002/cam4.71645

Figure Lengend Snippet: PRKDC and SLC25A13‐oriented drug framework identification for ESCC patients. (A) GSCA enrichment analysis for identification of sensitive drugs targeting PRKDC and SLC25A13. (B,C) Sensitivity analysis of drugs for ESCC patients. (D) CCK‐8 assays for optimum concentration of Navitoclax and BX‐912 in KYSE150 cell lines. (E) CCK‐8 assay for evaluation of Navitoclax and BX‐912 in KYSE150 cell line growth. (F) Wound‐healing assays following Navitoclax and BX‐912 treatment in KYSE150 cells. Data was presented as mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bar = 200 μm.

Article Snippet: BX‐912 (HY‐11005) and Navitoclax (HY‐10087) were purchased from MCE (China).

Techniques: CCK-8 Assay, Concentration Assay

PRKDC and SLC25A13‐oriented drug framework identification for ESCC patients. (A) GSCA enrichment analysis for identification of sensitive drugs targeting PRKDC and SLC25A13. (B,C) Sensitivity analysis of drugs for ESCC patients. (D) CCK‐8 assays for optimum concentration of Navitoclax and BX‐912 in KYSE150 cell lines. (E) CCK‐8 assay for evaluation of Navitoclax and BX‐912 in KYSE150 cell line growth. (F) Wound‐healing assays following Navitoclax and BX‐912 treatment in KYSE150 cells. Data was presented as mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bar = 200 μm.

Journal: Cancer Medicine

Article Title: Identification and Validation of cGAS ‐ STING Pathway‐Associated Predictive and Therapeutic Models for Esophageal Squamous Cell Cancer Patients via Artificial Intelligence and Multi‐Omics

doi: 10.1002/cam4.71645

Figure Lengend Snippet: PRKDC and SLC25A13‐oriented drug framework identification for ESCC patients. (A) GSCA enrichment analysis for identification of sensitive drugs targeting PRKDC and SLC25A13. (B,C) Sensitivity analysis of drugs for ESCC patients. (D) CCK‐8 assays for optimum concentration of Navitoclax and BX‐912 in KYSE150 cell lines. (E) CCK‐8 assay for evaluation of Navitoclax and BX‐912 in KYSE150 cell line growth. (F) Wound‐healing assays following Navitoclax and BX‐912 treatment in KYSE150 cells. Data was presented as mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bar = 200 μm.

Article Snippet: BX‐912 (HY‐11005) and Navitoclax (HY‐10087) were purchased from MCE (China).

Techniques: CCK-8 Assay, Concentration Assay